Guidance

Digital mental health technology: qualification and classification

Helping manufacturers define the characteristics of their devices and determine the appropriate regulatory qualification and classification.

Documents

Digital mental health technology: device characterisation, regulatory qualification and classification

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Digital mental health technologies (DMHTs) are software products and related hardware that aim to support mental health and wellbeing. For the purposes of regulation, there are two important characteristics: 

  1. Intended purpose: what the manufacturer intends it to be used for. For example, whether it is to support wellbeing or to aid treatment of a mental health condition.

  2. Functionality: how the product works, and how the different applications of the DMHT are delivered through the device. For example, functionalities can include, but are not limited to, education modules about understanding mental health and wellbeing, AI algorithms and chatbots.  

If the device is intended to have a medical purpose and the product functionality is considered complex, a DMHT needs to be regulated as a software as a medical device (SaMD) product. This means that the manufacturer must meet the requirements of the medical device regulations. They will have to evidence product safety and effectiveness according to recognised standards.  

This guidance document helps manufacturers identify the specific characteristics of their DMHT and determine whether it is considered as SaMD. If it is SaMD, the guidance will help determine the appropriate device classification.

Class I is for the lowest risk medical devices, which manufacturers can self-certify before putting them on the market. Class IIa, IIb, and III are for increasingly higher-risk medical devices and will require approved/notified body assessment to achieve the appropriate regulatory certification in the UK or Europe.

Updates to this page

Published 3 February 2025

Sign up for emails or print this page